These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37723577)

  • 1. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
    Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
    Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
    van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
    Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.
    Deodhar A; van der Heijde D; Sieper J; Van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Ostor A; Combe B; Sui Y; Chu AD; Song IH
    Arthritis Rheumatol; 2022 Jan; 74(1):70-80. PubMed ID: 34196498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.
    van der Heijde D; Deodhar A; Maksymowych WP; Sieper J; Van den Bosch F; Kim TH; Kishimoto M; Östör AJ; Combe B; Sui Y; Duan Y; Wung PK; Song IH
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35896281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
    van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J
    Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis.
    Navarro-Compán V; Baraliakos X; Magrey M; Östör A; Saffore CD; Mittal M; Song IH; Ganz F; Stigler J; Deodhar A
    Rheumatol Ther; 2023 Jun; 10(3):679-691. PubMed ID: 36820984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety.
    Tang H; Liu X; Zhao J; Tang Z; Zheng Z; Bai W
    Clin Rheumatol; 2024 Aug; 43(8):2391-2402. PubMed ID: 38874670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
    Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A
    Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Advanced Therapies in the Treatment of Radiographic Axial Spondyloarthritis or Ankylosing Spondylitis as Evaluated by the ASDAS Low Disease Activity Criteria.
    Baraliakos X; Saffore CD; Collins EB; Parikh B; Ye X; Walsh JA
    Rheumatol Ther; 2024 Aug; 11(4):989-999. PubMed ID: 38858318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
    Rubbert-Roth A; Kato K; Haraoui B; Rischmueller M; Liu Y; Khan N; Camp HS; Xavier RM
    Rheumatol Ther; 2024 Oct; 11(5):1197-1215. PubMed ID: 39031276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
    Mease P; Setty A; Papp K; Van den Bosch F; Tsuji S; Keiserman M; Carter K; Li Y; McCaskill R; McDearmon-Blondell E; Wung P; Tillett W
    Clin Exp Rheumatol; 2023 Nov; 41(11):2286-2297. PubMed ID: 37404160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2022 Feb; 81(1):71-76. PubMed ID: 33340056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Deodhar A; Van den Bosch F; Poddubnyy D; Maksymowych WP; van der Heijde D; Kim TH; Kishimoto M; Blanco R; Duan Y; Li Y; Pangan AL; Wung P; Song IH
    Lancet; 2022 Jul; 400(10349):369-379. PubMed ID: 35908570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
    Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
    Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
    van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
    Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.
    Marzo-Ortega H; Sieper J; Kivitz AJ; Blanco R; Cohen M; Pavelka K; Delicha EM; Stefanska A; Richards HB; Rohrer S
    Lancet Rheumatol; 2020 Jun; 2(6):e339-e346. PubMed ID: 38273597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND.
    van Vollenhoven RF; Hall S; Wells AF; Meerwein S; Song Y; Tanjinatus O; Fleischmann R
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
    Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.